Vericel Corporation (NASDAQ:VCEL – Free Report) – Research analysts at HC Wainwright reduced their Q3 2026 EPS estimates for shares of Vericel in a research note issued to investors on Friday, July 31st. HC Wainwright analyst S. Ramakanth now anticipates that the biotechnology company will earn $0.02 per share for the quarter, down from their previous estimate of $0.12. HC Wainwright also issued estimates for Vericel’s Q1 2027 earnings at ($0.13) EPS, FY2027 earnings at $0.68 EPS, FY2028 earnings at $1.13 EPS, FY2029 earnings at $1.61 EPS and FY2030 earnings at $2.21 EPS. GAMMA Investing LLC now owns 1,886 shares of the biotechnology company’s stock worth $84,000 after purchasing an additional 283 shares during the period. Vericel Company Profile(Get Free Report)Vericel Corporation is a biotechnology company specializing in the development, manufacturing and commercialization of cell-based therapies for patients with severe diseases and conditions.